Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Shubham Pant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9281-480X; OpenAlex author ID A5050096338, A5084349853, A5138536246, A5153382207; NIH RePORTER profile ID 10911308. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 3, last author 6)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
1
Collaborators
222
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: 2 papers, 1 trial · 2020: 8 papers · 2021: 5 papers · 2022: 5 papers, 1 trial · 2023: 5 papers, 1 grant · 2024: 4 papers · 2025: 8 papers · 2026: 9 papers

Papers 50 of 52

  1. Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s12029-026-01601-z↗
  2. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  3. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  4. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  5. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  6. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  7. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Last author DOI 10.1093/oncolo/oyag071↗
  8. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  9. Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications. Co-author DOI 10.1158/1078-0432.ccr-26-0344↗
  10. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  11. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  12. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  13. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  14. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  15. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  16. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  17. Novel Therapies for Pancreatic Cancer. Last author DOI 10.1200/op.24.00279↗
  18. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  19. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
  20. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  21. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081↗
  22. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Tri… Last author DOI 10.1007/s12029-023-00930-7↗
  23. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  24. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  25. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  26. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  27. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  28. Precision Oncology With Germline and Somatic Sequencing in Pancreatic Cancer: The Time Is Now. First author DOI 10.1097/mpa.0000000000002026↗
  29. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-21-1248↗
  30. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  31. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. Co-author DOI 10.1186/s12885-021-09095-7↗
  32. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  33. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  34. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  35. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. First author DOI 10.1200/edbk_321255↗
  36. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Last author DOI 10.21037/jgo-20-569↗
  37. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  38. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  39. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
  40. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Last author DOI 10.1016/j.pan.2020.01.005↗
  41. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  42. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  43. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗
  44. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Last author DOI 10.21037/jgo.2019.10.05↗
  45. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. Co-author DOI 10.1016/j.vgie.2019.02.009↗
  46. PARP inhibition - opportunities in pancreatic cancer. Co-author DOI 10.1038/s41571-019-0257-6↗
  47. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  48. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  49. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Co-author DOI 10.1371/journal.pone.0118933↗
  50. Molecular Targeted Intervention for Pancreatic Cancer. Co-author DOI 10.3390/cancers7030850↗

Trials 3

  1. A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. Principal investigator NCT05497778↗
  2. Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer Principal investigator NCT04132505↗
  3. FOLFIRINOX in Patients With Inoperable Pancreatic Cancer Principal investigator NCT01359007↗

Grants 1

  1. Administrative Core P50CA221707↗

Closest collaborators

The 25 strongest of 222 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert A. Wolff · 24 shared papers, 2019–2026 · strength 3.31
  2. Matthew H. G. Katz · 19 shared papers, 2019–2026 · strength 2.52
  3. Eugene Jon Koay · 17 shared papers, 2019–2026 · strength 2.37
  4. Ching-Wei David Tzeng · 18 shared papers, 2019–2025 · strength 2.35
  5. Anirban Maitra · 10 shared papers, 1 shared grant, 2019–2026 · strength 2.14
  6. Michael James Overman · 15 shared papers, 2020–2026 · strength 2.08
  7. Brandon George Smaglo · 10 shared papers, 2023–2026 · strength 1.80
  8. Gauri Rajani Varadhachary · 12 shared papers, 1 shared grant, 2019–2025 · strength 1.79
  9. Eileen Mary O'Reilly · 10 shared papers, 2014–2026 · strength 1.75
  10. Zev A. Wainberg · 9 shared papers, 2021–2026 · strength 1.73
  11. Jonathan D. Mizrahi · 8 shared papers, 2020–2026 · strength 1.52
  12. Michael P. Kim · 12 shared papers, 2020–2025 · strength 1.49
  13. Milind M. Javle · 13 shared papers, 2020–2024 · strength 1.46
  14. Naruhiko Ikoma · 11 shared papers, 2020–2026 · strength 1.46
  15. Ethan Bernard Ludmir · 8 shared papers, 2022–2026 · strength 1.30
  16. Tanios Bekaii‐Saab · 8 shared papers, 2014–2026 · strength 1.27
  17. Dan Zhao · 6 shared papers, 2024–2026 · strength 1.15
  18. Jeffrey E. Lee · 9 shared papers, 2020–2025 · strength 1.10
  19. Jane Elizabeth Rogers · 7 shared papers, 2020–2026 · strength 1.07
  20. David R. Fogelman · 10 shared papers, 2014–2026 · strength 1.03
  21. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  22. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  23. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  24. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  25. Eric Van Cutsem · 5 shared papers, 2023–2026 · strength 0.99

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.